1stOncology™: Cancer Intelligence Service – Page 12490 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Agenus Announces Investor Day on February 20, 2020

On February 6, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, reported it will hold an Investor Day Thursday, February 20, 2020 (Press release, Agenus, FEB 6, 2020, View Source [SID1234553925]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The Investor Day will present:

Clinical data from pre-planned interim analyses of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4);
Clinical data from a dose-escalation study of AGEN1181, a novel multi-functional T cell engager.
Date:

Thursday, February 20, 2020

Time:

9:00 – 11:00AM

Location:

New York, NY (by invitation only)

Event details: agenusbio.com

Presenters will include global experts in immune-oncology, Dr. Chuck Drake, Co-Director, Cancer Immunotherapy Program, Columbia University Herbert Irving Comprehensive Cancer Center, and Dr. Bradley Monk, M.D., FACS, FACOG, Co‐Director of GOG Partners, Arizona Oncology (US Oncology Network) and Professor, Gynecologic Oncology at University of Arizona, and Creighton University, Medical Director of US Oncology Research Gynecology program in Phoenix, Arizona.

The event will be webcast live an may be accessed by visiting the "Events & Presentations" page within the Investors section of the Agenus website at www.agenusbio.com or by using the link below. A replay of the webcast, as well as a copy of the slide presentations that will be presented at the event, will be available on the Agenus website following the event.

Please note that in-person attendance is by invitation only and advanced registration is required. If you are interested in attending or for more information, please contact Regina Grebla, Agenus Investor Relations, at [email protected].

Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum Oncology Day on February 13th

On February 6, 2020 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that an overview of the company’s business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum Oncology Day being held in New York (Press release, Spectrum Pharmaceuticals, FEB 6, 2020, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-guggenheim-0 [SID1234553920]). The company presentation is on Thursday, February 13, 2020, at 4:00 PM EST.

Replimune to Present at Two Upcoming Investor Conferences

On February 6, 2020 Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that members from the Replimune management team will participate in fireside chats and host investor meetings at the following two conferences (Press release, Replimune, FEB 6, 2020, View Source [SID1234553918]).

Guggenheim Healthcare Talks Forum – Oncology Day 2020
Date: Thursday, February 13, 2020
Presentation Time: 2:30 pm ET
Location: St. Regis in New York, NY

9th Annual SVB Leerink Global Healthcare Conference
Date: Tuesday, February 25, 2020
Presentation Time: 11:00 am ET
Location: Lotte New York Palace in New York, NY

ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference

On February 6, 2020 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the BIO CEO & Investor Conference being held at the Marriott Marquis in New York, February 10-11, 2020 (Press release, ProMIS Neurosciences, FEB 6, 2020, View Source [SID1234553917]).

ProMIS’ Executive Chairman, Eugene Williams will provide a brief update on the company and present supportive data for the Company’s antibody programs targeting neurodegenerative diseases. Mr. Williams’ presentation is scheduled for February 11, 2020 at 3:00 pm ET. Webcasting is not available for this event.

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

On February 6, 2020 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that the underwriters of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously announced by Chi-Med on January 21, 2020 and January 23, 2020 (the "Offering"), have given notice to Chi-Med that they are exercising their over-allotment option (Press release, Hutchison China MediTech, FEB 6, 2020, https://www.chi-med.com/chi-med-announces-the-exercise-of-underwriters-over-allotment-option-for-public-offering-of-adss/ [SID1234553915]). The underwriters have elected to purchase an additional 333,663 ADSs at the Offering price of US$25.00 per ADS, raising approximately an additional US$8.3 million in gross proceeds for the Company and bringing the total gross proceeds of the Offering to approximately US$118.3 million. Closing of the over-allotment portion is expected to occur on February 10, 2020. After the closing, the total number of ADSs sold by Chi-Med in the Offering will have increased to 4,733,663.

BofA Securities, Inc., Goldman Sachs (Asia) L.L.C. and Morgan Stanley & Co. LLC (in alphabetical order) are acting as joint global coordinators and joint bookrunners for the Offering. Deutsche Bank Securities Inc. and HSBC Securities (USA) Inc. are acting as joint bookrunners, and Canaccord Genuity LLC, CLSA Limited and Panmure Gordon (UK) Limited are acting as co-managers.